This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
72
Administered as per the protocol
Illinois Retina Associates
Oak Park, Illinois, United States
RECRUITINGTennessee Retina PC
Nashville, Tennessee, United States
RECRUITINGOccurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through Week 24
Concentrations of REGN7041 in serum
Time frame: Through Week 24
Incidence of Anti-Drug Antibodies (ADAs) to REGN7041 in serum
Time frame: Through Week 24
Magnitude of ADAs to REGN7041 in serum
Time frame: Through Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.